| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -51.0 | -67.3 |
| EPS (diluted, $ a share) | $-0.46 | $-0.78 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: DFTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Definium Therapeutics, Inc.: key numbers
- Share price
- $29.38Close, Nov 17
- Market cap
- $4.02B
- Shares outstanding
- 136.9MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Definium Therapeutics, Inc.
All →Definium Therapeutics Earnings Call: Key Takeaways
Definium Therapeutics reported positive Phase 3 results for DT120 in GAD and MDD, maintaining a strong $1.05 billion cash position to fund operations through 2030 while preparing for a 2027 NDA filing.
- Call
- Nov 9, 2026, 4:30 PM ET
Definium Therapeutics Financial Results
Definium Therapeutics reported Q3 2026 financial results, highlighting a strong cash position of $1.05 billion. The company achieved positive Phase 3 topline results for DT120 ODT in generalized anxiety disorder and received FDA Breakthrough Therapy Designation for the same candidate in major depressive disorder.
- Term
- Q3 2026
“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions.”
Rob Barrow, Chief Executive Officer
“With Breakthrough Therapy designation in MDD and Ascend progressing, we continue to advance our late-stage program while building the capabilities needed to prepare for potential approval and commercialization. Beyond DT120, we believe DT402 represents an exciting opportunity and its initial results support continued development as we work to deliver differentiated therapies for patients with significant unmet needs.”
Rob Barrow, Chief Executive Officer
Definium Therapeutics CFO Brandi Roberts Sells $123K of Stock
Brandi Roberts, CFO, sold 3,377 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $123K in total on Sep 25, 2026. Shares held after the trade: 394,528 (-0.8%).
- Value
- $123K
- Shares
- 3,377
- Price
- $36.57
- Role
- CFO
- Holding change
- -0.8%
- Trade date
- Sep 25, 2026
Definium Therapeutics CLO Mark Sullivan Sells $514K of Stock
Mark Sullivan, CLO, sold 14,051 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $514K in total on Sep 25, 2026. Shares held after the trade: 494,228 (-2.8%).
- Value
- $514K
- Shares
- 14,051
- Price
- $36.57
- Role
- CLO
- Holding change
- -2.8%
- Trade date
- Sep 25, 2026
Definium Therapeutics Chief Commercial Officer Matthew T. Wiley Sells $113K of Stock
Matthew T. Wiley, Chief Commercial Officer, sold 3,097 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $113K in total on Sep 25, 2026. Shares held after the trade: 359,036 (-0.9%).
- Value
- $113K
- Shares
- 3,097
- Price
- $36.57
- Role
- Chief Commercial Officer
- Holding change
- -0.9%
- Trade date
- Sep 25, 2026
Definium Therapeutics CEO Robert Barrow Sells $1.15M of Stock
Robert Barrow, CEO, sold 31,550 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $1.15M in total on Sep 25, 2026. Shares held after the trade: 2,213,090 (-1.4%).
- Value
- $1.15M
- Shares
- 31,550
- Price
- $36.57
- Role
- CEO
- Holding change
- -1.4%
- Trade date
- Sep 25, 2026